Some studies, articles, links :
“Saccharomyces boulardii is a non-pathogenic, non-colonizing yeast with probiotic properties used in many countries as both a preventive and therapeutic agent for diarrhoea and other gastrointestinal disorders and not related to the yeast group to which Candida belongs.
Supplementation may be useful for controlling diarrhoea associated with antibiotic use and the consumption of unusual foods while travelling.
Saccharomyces boulardii taken orally produces lactic acid and some B vitamins as it becomes established. During use, friendly probiotic bacteria are allowed to colonize in the GI tract making Saccharomyces boulardii particularly beneficial in balancing intestinal microbiology. It is then eliminated after supplementation is stopped.
S. boulardii is being used both in the pharmaceutical and in nutritional industries.
----- ------
This microorganism has a bioregulatory effect on the intestinal flora helping to maintain a normal balance of friendly bacteria in the intestines modulating immunity by boosting intestinal secretion of IgA. The protective effect ofSaccharomyces boulardii involves several types of activity in the epithelial tissue of the digestive tract, including inactivation of bacterial toxins, stimulation of intestinal immune response, and release of polyamines.
The clinical activity of S. boulardii has been documented in various types of diarrhoea and is especially relevant to antibiotic-associated diarrhoea and recurrent Clostridium difficile intestinal infections; its particular capacity to survive gastric acidity and to resist all commonly used antibiotics (except anti-fungals) makes it a useful remedy for diarrhoea brought on by antibiotics.
Research has found that S. boulardii may support gut function with many conditions, including inflammatory bowel disease, irritable bowel syndrome and traveler's diarrhoea.
www.gnosis-bio.com/biooptima-boulardii.php Systematic review and meta-analysis of Saccharomyces boulardii in adult patients
www.ncbi.nlm.nih.gov/pmc/articles/PMC2868213/ Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
www.ncbi.nlm.nih.gov/pmc/articles/PMC3296087/ Prevention of Clostridium difficile infection with Saccharomyces boulardii: A systematic review
www.ncbi.nlm.nih.gov/pmc/articles/PMC2805518/ Probiotic use in clinical practice: what are the risks?1,2,3
ajcn.nutrition.org/content/83/6/1256.full S. Boulardii effects on GI diseases
www.horizonpress.com/cimb/v/v11/47.pdf Protection against increased intestinal permeability and bacterial trans
location induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii.
www.ncbi.nlm.nih.gov/pubmed/20936479 Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission.
www.ncbi.nlm.nih.gov/pubmed/18584523 Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders
www.ncbi.nlm.nih.gov/pmc/articles/PMC3296087/ Saccharomyces boulardii in maintenance treatment of Crohn's disease.
www.ncbi.nlm.nih.gov/pubmed/10961730 Probiotics for Crohn's disease: what have we learned?
www.ncbi.nlm.nih.gov/pmc/articles/PMC1856223/ Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis.
www.ncbi.nlm.nih.gov/pubmed/21903765 Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii.
www.ncbi.nlm.nih.gov/pubmed/19706150A pilot trial of Saccharomyces boulardii in ulcerative colitis.
www.ncbi.nlm.nih.gov/pubmed/12840682/"when S. boulardii is given to antibiotic-shocked mice or patients with diarrhea, normal microbiota is re-established rapidly"
Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii.
www.ncbi.nlm.nih.gov/pubmed/18511310/Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition.
www.ncbi.nlm.nih.gov/pubmed/16273644/ CONCLUSION: Sb-induced increase of fecal SCFA concentrations (especially butyrate) may explain the preventive effects of this yeast on TEN-induced diarrhea.
Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study.
www.ncbi.nlm.nih.gov/pubmed/8465554/